ホーム>>Lipids>> Sterol Lipids>>Beauveriolide III

Beauveriolide III

カタログ番号GC46912

Beauveriolide III は、マウス マクロファージにおける脂肪滴形成の阻害剤です 。

Products are for research use only. Not for human use. We do not sell to patients.

Beauveriolide III 化学構造

Cas No.: 221111-70-2

サイズ 価格 在庫数
500 μg
$231.00
Please Inquire
2.5 mg
$926.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Beauveriolide III is a cyclodepsipeptide that has been found in Beauveria and an inhibitor of lipid droplet formation.1 It inhibits lipid droplet formation when used at concentrations of 3 and 10 µM, as well as inhibits cholesterol synthesis (IC50 = 0.41 µM), in primary mouse peritoneal macrophages.1,2 Beauveriolide III also inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity in mouse macrophage membranes (IC50 = 5.5 µM).2 Beauveriolide III (25 and 50 mg/kg) reduces the size of aortic atherosclerotic lesions in Ldlr-/- and ApoE-/- mouse models of atherosclerosis.

1.Namatame, I., Tomoda, H., Si, S., et al.Beauveriolides, specific inhibitors of lipid droplet formation in mouse macrophages, produced by Beauveria sp. FO-6979J. Antibiot. (Tokyo)52(1)1-6(1999) 2.Namatame, I., Tomoda, H., Ishibashi, S., et al.Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophagesProc. Nat. Acad. Sci. USA101(3)737-742(2004)

レビュー

Review for Beauveriolide III

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Beauveriolide III

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.